RECRUITINGOBSERVATIONAL

13C-Glucose Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients.

Metabolic Tracing of Tumour and T Cells in the Ascites of Ovarian Cancer Patients

About This Trial

The objective of the study is to investigate the metabolism of cells in the ascites tumour microenvironment of ovarian cancer patients. This observational study involves intravenous infusion of \[U-13C\]glucose into patients during standard paracentesis.

Who May Be Eligible (Plain English)

Who May Qualify: - Ovarian cancer - Any stage or grade of disease - Ascites fluid that requires draining - Any treatment regimen - Primary or recurrent ascites - Understands the concept of the study and give willing to sign a consent form. Who Should NOT Join This Trial: - Participants must not have diabetes or abnormal hemoglobin A1C levels. - The patient's glucose levels must be between 4 - 11.1 mM before administering an infusion. This is to ensure that patients are within normal blood glucose levels, as described by Diabetes Canada. - Participants cannot receive chemotherapy treatment during the 5 hour duration of the experiment as it may compromise the integrity of the data. Always talk to your doctor about whether this trial is right for you.

Original Eligibility Criteria

View original clinical language

Inclusion Criteria: * Ovarian cancer * Any stage or grade of disease * Ascites fluid that requires draining * Any treatment regimen * Primary or recurrent ascites * Understands the concept of the study and give informed consent. Exclusion Criteria: * Participants must not have diabetes or abnormal hemoglobin A1C levels. * The patient's glucose levels must be between 4 - 11.1 mM before administering an infusion. This is to ensure that patients are within normal blood glucose levels, as described by Diabetes Canada. * Participants cannot receive chemotherapy treatment during the 5 hour duration of the experiment as it may compromise the integrity of the data.

Treatments Being Tested

DIETARY_SUPPLEMENT

[U-13C]Glucose

Patients are intravenously infused with 28g of \[U-13C\]glucose over a 5 hour period. Briefly, \[U-13C\]glucose will be provided by intravenous line containing 8g of \[U-13C\]glucose in 60 mL over 10 min. After 10 minutes, 4g of \[U-13C\]glucose will be administered over an hour. This process will continue until the patient's ascites is drained, or after 5 hours. We will monitor blood glucose levels during infusions using a continuous glucose monitor.

Locations (1)

Jennifer Rauw

Victoria, British Columbia, Canada